Regenxbio Inc expected to post earnings of 48 cents a share - Earnings Preview

Regenxbio

09/05/2025 21:05

Regenxbio Inc RGNX.OQ RGNX.O is expected to show a rise in quarterly revenue when it reports  results on May 12 for the period ending March 31 2025

The Rockville Maryland-based  company is expected to report a 552.7% increase in revenue to $101.969 million from $15.62 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Regenxbio Inc is for earnings of 48 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.7% in the last three months. ​

Wall Street's median 12-month price target for Regenxbio Inc is $31.50​, above​ its last closing price of $7.15. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.24
-1.15
-1.01
Beat
11.9
Sep. 30 2024
-1.11
-1.12
-1.17
Missed
-4.3
Jun. 30 2024
-1.30
-1.29
-1.05
Beat
18.7​
Mar. 31 2024
-1.29
-1.26
-1.33
Missed
-5.6
​​Dec. 31 2023
-1.30
-1.27
-1.43
Missed
-12.5
Sep. 30 2023
-1.56
-1.52
-1.41
Beat
7.1​
Jun. 30 2023
-1.43
-1.38
-1.66
Missed
-19.9
Mar. 31 2023
-1.60
-1.54
-1.53
Beat
0.4

This summary was machine generated May 9 at 20:05 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)